Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. Vredenburgh JJ, et al. Among authors: threatt s. Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531816 Free PMC article. Clinical Trial.
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Threatt S, Friedman HS. Quinn JA, et al. Among authors: threatt s. Clin Cancer Res. 2009 Feb 1;15(3):1064-8. doi: 10.1158/1078-0432.CCR-08-2130. Clin Cancer Res. 2009. PMID: 19188181 Free PMC article. Clinical Trial.
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE 2nd, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Reardon DA, et al. Among authors: threatt s. J Neurooncol. 2011 Jun;103(2):371-9. doi: 10.1007/s11060-010-0403-6. Epub 2010 Sep 19. J Neurooncol. 2011. PMID: 20853132 Free PMC article. Clinical Trial.
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Vredenburgh JJ, et al. Among authors: threatt s. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):58-66. doi: 10.1016/j.ijrobp.2010.08.058. Epub 2010 Oct 30. Int J Radiat Oncol Biol Phys. 2012. PMID: 21036490 Clinical Trial.
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: threatt s. Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16. Cancer. 2011. PMID: 21590689 Free PMC article. Clinical Trial.
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Reardon DA, et al. Among authors: threatt s. J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11. J Neurooncol. 2012. PMID: 21986722 Free PMC article. Clinical Trial.
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE 2nd, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Reardon DA, et al. Among authors: threatt s. J Neurooncol. 2012 Jul;108(3):499-506. doi: 10.1007/s11060-012-0848-x. Epub 2012 Mar 10. J Neurooncol. 2012. PMID: 22407177 Free PMC article. Clinical Trial.
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
Thompson EM, Landi D, Brown MC, Friedman HS, McLendon R, Herndon JE 2nd, Buckley E, Bolognesi DP, Lipp E, Schroeder K, Becher OJ, Friedman AH, McKay Z, Walter A, Threatt S, Jaggers D, Desjardins A, Gromeier M, Bigner DD, Ashley DM. Thompson EM, et al. Among authors: threatt s. Lancet Child Adolesc Health. 2023 Jul;7(7):471-478. doi: 10.1016/S2352-4642(23)00031-7. Epub 2023 Mar 30. Lancet Child Adolesc Health. 2023. PMID: 37004712 Free PMC article. Clinical Trial.
Convection-Enhanced Delivery in the Treatment of Glioblastoma.
Brown CB, Jacobs S, Johnson MP, Southerland C, Threatt S. Brown CB, et al. Among authors: threatt s. Semin Oncol Nurs. 2018 Dec;34(5):494-500. doi: 10.1016/j.soncn.2018.10.004. Epub 2018 Nov 2. Semin Oncol Nurs. 2018. PMID: 30392757 Review.
14 results